Earnings Surprises
Biggest EPS beats and misses, ranked by post-earnings price reaction. Free data, no paywall.
Ranked by EPS surprise % (highest first). Price reaction = day after report.
| # | Symbol | Company | Sector | Date | EPS Actual | EPS Est. | Surprise | Price Reaction |
|---|---|---|---|---|---|---|---|---|
| 1 | Galapagos N.V. | Healthcare | Feb 23, 2026 | $16.38 | $1.00 | +1538% | +1.8% | |
| 2 | BioCryst Pharmaceuticals, Inc. | Healthcare | Feb 26, 2026 | $1.12 | $0.07 | +1500% | +15.9% | |
| 3 | Omada Health | Healthcare | Mar 5, 2026 | $0.13 | $0.01 | +1429% | +3.9% | |
| 4 | ACADIA Pharmaceuticals Inc. | Healthcare | Feb 25, 2026 | $1.60 | $0.14 | +1068% | +0.2% | |
| 5 | iRhythm Technologies, Inc. | Healthcare | Feb 19, 2026 | $0.17 | $0.02 | +750% | -1.9% | |
| 6 | STAAR Surgical Company | Healthcare | May 13, 2026 | $0.38 | $0.05 | +601% | +13.6% | |
STAAR is off to a strong start in 2026, as reflected in our first quarter financial results. We have made meaningful advancements against our core objectives of Revenue Growth and Profit Expansion. | ||||||||
| 7 | CareDx, Inc | Healthcare | Feb 24, 2026 | $0.12 | $0.02 | +503% | -1.8% | |
| 8 | Innoviva, Inc. | Healthcare | Feb 25, 2026 | $1.94 | $0.34 | +471% | +0.5% | |
| 9 | Fortrea Holdings Inc. | Healthcare | May 5, 2026 | $0.16— Maintained | $0.03 | +433% | +27.7% | |
We started the year strong, focused on delivering for our clients with excellence and making advances in our strategic journey back to growth and margin expansion. | ||||||||
| 10 | Alignment Healthcare, Inc. | Healthcare | Apr 30, 2026 | $0.05↑ Raised | $0.01 | +400% | -6.7% | |
John Kao, founder and CEO Our first-quarter performance demonstrates that Alignment continues to grow with discipline. We expanded our profitability by executing across sales, clinical operations and cost management, even as the Medicare Advantage environment continues to change. | ||||||||
| 11 | Arcutis Biotherapeutics, Inc. | Healthcare | Feb 25, 2026 | $0.13 | $0.03 | +333% | +5.9% | |
| 12 | BioLife Solutions, Inc. | Healthcare | May 7, 2026 | $0.04— Maintained | $0.01 | +300% | +1.3% | |
We delivered a solid start to 2026, with first quarter revenue up 25% year-over-year and adjusted EBITDA of $6.2 million. Healthy demand for our biopreservation media and growth across our broader product portfolio reinforces our market leading position. | ||||||||
| 13 | LifeStance Health Group, Inc. | Healthcare | May 7, 2026 | $0.04↑ Raised | $0.01 | +300% | +4.5% | |
We delivered an exceptional quarter to begin the year, highlighted by strong revenue growth of 21%, net income growth of $13.5 million, and Adjusted EBITDA growth of 48%. | ||||||||
| 14 | Astrana Health, Inc. | Healthcare | Mar 2, 2026 | $0.54 | $0.15 | +260% | +20.6% | |
| 15 | Hims & Hers Health, Inc. | Healthcare | Feb 23, 2026 | $0.07 | $0.02 | +250% | -1.1% | |
| 16 | Supernus Pharmaceuticals, Inc. | Healthcare | Feb 24, 2026 | $0.92 | $0.28 | +229% | +11.1% | |
| 17 | Sarepta Therapeutics, Inc. | Healthcare | May 6, 2026 | $3.16— Maintained | $0.98 | +224% | -4.5% | |
We entered 2026 with clear priorities—stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we believe can define Sarepta’s next era. | ||||||||
| 18 | CareDx, Inc | Healthcare | Apr 28, 2026 | $0.34↑ Raised | $0.11 | +209% | -4.8% | |
John W. Hanna, President and CEO Our team delivered another quarter of record growth, driven by continued momentum in our Precision Medicine Testing Services and Patient and Digital Solutions businesses. | ||||||||
| 19 | BeOne Medicines Ltd. | Healthcare | May 6, 2026 | $1.96↑ Raised | $0.73 | +168% | +6.6% | |
These strong first-quarter results reinforce BeOne’s continued growth as a global oncology leader, driven by disciplined commercial execution, and underpinned by our established hematology leadership, and an impressive, rapidly emerging solid tumor pipeline. | ||||||||
| 20 | Astrana Health, Inc. | Healthcare | May 7, 2026 | $0.74 | $0.29 | +155% | +11.5% | |
| 21 | Acadia Healthcare Company, Inc. | Healthcare | Feb 25, 2026 | $0.07 | $0.03 | +133% | +29.8% | |
| 22 | Neogen Corporation | Healthcare | Apr 9, 2026 | $0.09 | $0.04 | +125% | -9.3% | |
| 23 | Supernus Pharmaceuticals, Inc. | Healthcare | May 5, 2026 | $0.59— Maintained | $0.28 | +111% | +5.9% | |
Our first quarter results reflect a strong start to the year, including a 56% year-over-year increase in combined revenues of our growth products. | ||||||||
| 24 | Xeris Biopharma Holdings, Inc. | Healthcare | Mar 2, 2026 | $0.06 | $0.03 | +100% | -2.9% | |
| 25 | Liquidia Corporation | Healthcare | Mar 5, 2026 | $0.15 | $0.08 | +87.5% | +4.8% | |
STAAR is off to a strong start in 2026, as reflected in our first quarter financial results. We have made meaningful advancements against our core objectives of Revenue Growth and Profit Expansion.
We started the year strong, focused on delivering for our clients with excellence and making advances in our strategic journey back to growth and margin expansion.
Our first-quarter performance demonstrates that Alignment continues to grow with discipline. We expanded our profitability by executing across sales, clinical operations and cost management, even as the Medicare Advantage environment continues to change.
We delivered a solid start to 2026, with first quarter revenue up 25% year-over-year and adjusted EBITDA of $6.2 million. Healthy demand for our biopreservation media and growth across our broader product portfolio reinforces our market leading position.
We delivered an exceptional quarter to begin the year, highlighted by strong revenue growth of 21%, net income growth of $13.5 million, and Adjusted EBITDA growth of 48%.
We entered 2026 with clear priorities—stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we believe can define Sarepta’s next era.
Our team delivered another quarter of record growth, driven by continued momentum in our Precision Medicine Testing Services and Patient and Digital Solutions businesses.
These strong first-quarter results reinforce BeOne’s continued growth as a global oncology leader, driven by disciplined commercial execution, and underpinned by our established hematology leadership, and an impressive, rapidly emerging solid tumor pipeline.
Our first quarter results reflect a strong start to the year, including a 56% year-over-year increase in combined revenues of our growth products.
Ranked by EPS miss % (worst first). Price reaction = day after report.
| # | Symbol | Company | Sector | Date | EPS Actual | EPS Est. | Surprise | Price Reaction |
|---|---|---|---|---|---|---|---|---|
| 1 | Madrigal Pharmaceuticals, Inc. | Healthcare | Feb 19, 2026 | -$2.57 | $0.04 | -6525% | -11.5% | |
| 2 | Hims & Hers Health, Inc. | Healthcare | May 11, 2026 | -$0.40↑ Raised | $0.03 | -1675% | -11.5% | |
2026 is a defining year for Hims & Hers. We're not just growing, we're pulling away from the field on our path to becoming the world's largest consumer health platform. | ||||||||
| 3 | Mirum Pharmaceuticals, Inc. | Healthcare | Feb 25, 2026 | -$0.11 | $0.02 | -650% | -14.2% | |
| 4 | AdaptHealth Corp. | Healthcare | May 5, 2026 | -$0.06↑ Raised | $0.01 | -580% | -12.5% | |
The opening months of 2026 have set the stage for what will be a defining year for AdaptHealth. We completed the largest de novo expansion in the history of the home medical equipment industry, delivering revenue well ahead of our first quarter guidance. | ||||||||
| 5 | InnovAge Holding Corp. | Healthcare | May 5, 2026 | -$0.22↑ Raised | $0.06 | -467% | -0.9% | |
We delivered a solid third quarter, reflecting continued improvement in operating execution and financial performance. | ||||||||
| 6 | Nanobiotix S.A. | Healthcare | Mar 31, 2026 | -$0.46 | $0.30 | -251% | +11.4% | |
| 7 | BioMarin Pharmaceutical Inc. | Healthcare | Feb 23, 2026 | -$0.24 | $0.17 | -242% | -2.3% | |
| 8 | STAAR Surgical Company | Healthcare | Mar 3, 2026 | -$0.20 | $0.18 | -211% | +0.9% | |
| 9 | Brookdale Senior Living Inc. | Healthcare | May 6, 2026 | -$0.03 | $0.03 | -200% | -3.4% | |
| 10 | Warby Parker Inc. | Healthcare | Feb 26, 2026 | -$0.04 | $0.05 | -180% | +14.9% | |
| 11 | Avadel Pharmaceuticals plc | Healthcare | Mar 2, 2026 | -$0.05 | $0.08 | -163% | — | |
| 12 | BioCryst Pharmaceuticals, Inc. | Healthcare | May 6, 2026 | -$0.03 | $0.06 | -150% | -1.4% | |
| 13 | Cronos Group Inc. | Healthcare | Feb 26, 2026 | -$0.00 | $0.01 | -147% | -3.6% | |
| 14 | Azenta, Inc. | Healthcare | May 6, 2026 | -$0.04↓ Lowered | $0.10 | -140% | -24.5% | |
Our second quarter results fell short of our expectations, reflecting both execution gaps and a more cautious demand environment, particularly in North America. | ||||||||
| 15 | Telix Pharmaceuticals Limited | Healthcare | Feb 19, 2026 | -$0.01 | $0.03 | -135% | +20.0% | |
| 16 | Halozyme Therapeutics, Inc. | Healthcare | Feb 17, 2026 | -$0.24 | $2.15 | -111% | -7.8% | |
| 17 | QuidelOrtho Corporation | Healthcare | May 5, 2026 | -$0.04↓ Lowered | $0.37 | -111% | -11.8% | |
Our first quarter results were in line with our preliminary revenue announcement and reflected a significantly weaker respiratory season and business disruption in China and the Middle East. | ||||||||
| 18 | Nuvation Bio Inc. | Healthcare | May 4, 2026 | $0.01 | $0.12 | -91.7% | +7.6% | |
We are pleased with IBTROZI’s ongoing launch trends in the first quarter of 2026, as we continue to deepen its adoption across lines of therapy and make significant progress in becoming the standard of care for people living with advanced ROS1-positive NSCLC. | ||||||||
| 19 | Genmab A/S | Healthcare | Feb 17, 2026 | $0.05 | $0.46 | -89.1% | -2.9% | |
| 20 | Masimo Corporation | Healthcare | Feb 26, 2026 | $0.18 | $1.48 | -87.8% | +0.1% | |
| 21 | Amicus Therapeutics, Inc. | Healthcare | Feb 20, 2026 | $0.01 | $0.07 | -86.0% | +0.1% | |
| 22 | Privia Health Group, Inc. | Healthcare | May 7, 2026 | $0.02— Maintained | $0.08 | -75.0% | -3.9% | |
| 23 | Nutex Health, Inc. | Healthcare | Mar 5, 2026 | $1.61 | $5.56 | -71.0% | -16.8% | |
| 24 | BeOne Medicines Ltd. | Healthcare | Feb 26, 2026 | $0.58 | $1.60 | -63.8% | -10.0% | |
| 25 | Surgery Partners, Inc. | Healthcare | Mar 2, 2026 | $0.12 | $0.31 | -61.3% | -10.2% | |
2026 is a defining year for Hims & Hers. We're not just growing, we're pulling away from the field on our path to becoming the world's largest consumer health platform.
The opening months of 2026 have set the stage for what will be a defining year for AdaptHealth. We completed the largest de novo expansion in the history of the home medical equipment industry, delivering revenue well ahead of our first quarter guidance.
We delivered a solid third quarter, reflecting continued improvement in operating execution and financial performance.
Our second quarter results fell short of our expectations, reflecting both execution gaps and a more cautious demand environment, particularly in North America.
Our first quarter results were in line with our preliminary revenue announcement and reflected a significantly weaker respiratory season and business disruption in China and the Middle East.
We are pleased with IBTROZI’s ongoing launch trends in the first quarter of 2026, as we continue to deepen its adoption across lines of therapy and make significant progress in becoming the standard of care for people living with advanced ROS1-positive NSCLC.